Patent · US Active

Polypeptides antagonizing Wnt signaling in tumor cells

US11033636B2 · kind B2 · utility

1Cited by

1References

9Claims

0Family size

Assignee

Boehringer Ingelheim International GmbH · DE

Inventors

Vittoria Zinzalla · Wien, AT
Klaus-Peter Kuenkele · Perchtoldsdorf, AT
Marie-Ange Buyse · Merelbeke, BE
Karen Cromie · Merelbeke, BE
Stephanie Staelens · Wevelgem, BE
Beatrijs Strubbe · Zwijnaarde, BE

Key dates

Filing date	May 30, 2018
Grant date	Jun 15, 2021
Priority date	—
Expiry date	Feb 15, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides novel LRP5-binding polypeptides, and more specifically novel LRP5-binding immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.